Qtrypta FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 21, 2020.
Qtrypta is a proprietary formulation of zolmitriptan that utilizes Dermally-Applied Microarray (ADAM) technology (drug-coated microneedles) in development for the acute treatment of migraine.
Development Timeline for Qtrypta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.